Elasmogen Ltd is a next generation therapeutic biologics company discovering and developing soloMERs™ for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.
Employees: 11-50
Total raised: $2.56M
Founded date: 2016
Investors 1
| Date | Name | Website |
| 18.05.2022 | BGF Ventur... | bgf.co.uk |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.01.2020 | - | $2.56M | - |
Mentions in press and media 3
| Date | Title | Description |
| 17.10.2024 | Aberdeen Uni Slashes Equity Stake to Boost Spinouts | The University of Aberdeen is to take a new approach to fostering spinout culture by reducing its equity stake in an attempt to increase innovation and accelerate the commercialisation of intellectual property. The move makes Aberdeen one o... |
| 13.01.2020 | Scottish Elasmogen raises €2.3 million to beat cancer based on protein found in sharks | Aberdeen-based biotech startup Elasmogen has announced it has secured follow-on equity investment from Deepbridge Capital totalling €2.3 million, taking Deepbridge’s total investment in Elasmogen to €3.67 million. Elasmogen, founded 2016, h... |
| 08.01.2019 | Elasmogen Secures South Korea Deal | Aberdeen-based company Elasmogen has secured a landmark deal with a South Korean company to provide its groundbreaking technology. The biopharmaceutical company has entered a license agreement with drug development firm, ImmunoForge, to pro... |